Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PEDRAM GHASRI

Allopathic & Osteopathic Physicians Dermatology

NPI
1639429178
CMS profile
865269
Location
TARZANA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,681.44

145 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,681.44 145

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PEDRAM GHASRI

NPI 1639429178 · CMS profile ID 865269

Allopathic & Osteopathic Physicians / Dermatology

TARZANA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639429178?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PEDRAM GHASRI, NPI 1639429178, CMS profile ID 865269. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639429178?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PEDRAM GHASRI, NPI 1639429178, CMS profile ID 865269. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639429178?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PEDRAM GHASRI, NPI 1639429178, CMS profile ID 865269, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1639429178?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

145 matching records · $2,681.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 145 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–145 of 145.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $22.4504/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117561772 CMS
Regeneron Healthcare Solutions, Inc. $29.5004/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114055019 CMS
GENZYME CORPORATION $28.3004/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139873183 CMS
Janssen Biotech, Inc. $28.6204/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078344825 CMS
Dermavant Sciences, Inc. $25.3604/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127869307 CMS
E.R. Squibb & Sons, L.L.C. $20.6704/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456258 CMS
Journey Medical Corporation $43.1104/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100053631 CMS
Galderma Laboratories, L.P. $15.2604/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145299400 CMS
MAYNE PHARMA COMMERCIAL LLC $0.8304/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154663955 CMS
MAYNE PHARMA COMMERCIAL LLC $10.1604/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154663957 CMS
MAYNE PHARMA COMMERCIAL LLC $4.6204/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154663959 CMS
MAYNE PHARMA COMMERCIAL LLC $3.9104/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154663961 CMS
PFIZER INC. $25.0504/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131330989 CMS
Incyte Corporation $22.0703/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141229373 CMS
Dermavant Sciences, Inc. $4.1503/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127869305 CMS
GENZYME CORPORATION $10.2203/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139873181 CMS
Verrica Pharmaceuticals Inc. $23.2703/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118380948 CMS
Arcutis Biotherapeutics, Inc. $21.2603/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121068289 CMS
Regeneron Healthcare Solutions, Inc. $31.2903/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114055017 CMS
Dermavant Sciences, Inc. $11.8203/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127869301 CMS
Dermavant Sciences, Inc. $21.9403/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127869303 CMS
Incyte Corporation $10.1603/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141187220 CMS
Incyte Corporation $9.7103/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141263397 CMS
ABBVIE INC. $12.5903/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103792349 CMS
ABBVIE INC. $19.7703/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103792347 CMS
Arcutis Biotherapeutics, Inc. $6.5403/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121068291 CMS
Arcutis Biotherapeutics, Inc. $9.0703/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121068293 CMS
GENZYME CORPORATION $48.1303/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139873169 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $18.4802/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153815575 CMS
ABBVIE INC. $18.2102/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103792345 CMS
ABBVIE INC. $20.9602/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103792343 CMS
GENZYME CORPORATION $16.6502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139873161 CMS
PFIZER INC. $25.3802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131120666 CMS
Arcutis Biotherapeutics, Inc. $16.5902/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121068287 CMS
GENZYME CORPORATION $24.8402/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139873157 CMS
Janssen Biotech, Inc. $26.4501/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078345203 CMS
Regeneron Healthcare Solutions, Inc. $26.3901/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114055015 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $35.0301/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152190706 CMS
Incyte Corporation $8.1001/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141228426 CMS
ABBVIE INC. $18.6201/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103792341 CMS
Arcutis Biotherapeutics, Inc. $6.5001/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121068285 CMS
ABBVIE INC. $8.8801/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103792339 CMS
GENZYME CORPORATION $49.0201/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139873143 CMS
Janssen Biotech, Inc. $28.5101/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078344458 CMS
PFIZER INC. $2.1301/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131246959 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,836.89 75
PY2020 $1,669.96 86
PY2021 $1,601.68 91
PY2022 $1,850.80 97
PY2023 $2,595.14 148
PY2024 $2,681.44 145
PY2025 $3,906.65 209

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $212,474.34 50
PY2024 Principal investigator $48,418.15 14
PY2023 Principal investigator $41,877.00 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 UCB SA $7,350.00 12/24/2025 Non-covered Recipient Entity
Amicis Research Center
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656873
Principal investigator 1 Incyte Corporation $2,000.00 12/17/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240502075
Principal investigator 1 Incyte Corporation $2,000.00 12/17/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240502079
Principal investigator 1 Incyte Corporation $2,500.00 12/17/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240502084
Principal investigator 1 Incyte Corporation $2,966.00 12/17/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240502088
Principal investigator 1 Incyte Corporation $1,000.00 12/17/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240502093
Principal investigator 1 Incyte Corporation $12,000.00 12/17/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240502097
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,373.00 12/04/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431146
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $800.00 10/17/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431142
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $399.00 10/17/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431144
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 10/16/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192100498
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 10/16/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192160535
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 10/16/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162716
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 10/16/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162729
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 10/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192159930
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 10/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192160543
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 10/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162725
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 10/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162745
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 10/10/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192100490
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,478.00 10/10/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431140
Principal investigator 1 Eli Lilly and Company $7,520.00 10/02/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187874461
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $110.00 09/02/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431136
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $800.00 09/02/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431138
Principal investigator 1 GlaxoSmithKline, LLC. $2,716.01 08/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192160530
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,891.00 08/21/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431134
Principal investigator 1 GlaxoSmithKline, LLC. $117.30 07/22/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192160525
Principal investigator 1 GlaxoSmithKline, LLC. $4,415.56 07/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192160520
Principal investigator 1 GlaxoSmithKline, LLC. $2.07 06/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192100484
Principal investigator 1 GlaxoSmithKline, LLC. $2.07 06/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162741
Principal investigator 1 GlaxoSmithKline, LLC. $6,604.21 06/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162737
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,739.00 06/18/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431132
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 06/06/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162733
Principal investigator 1 GlaxoSmithKline, LLC. $18,987.45 05/27/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162721
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,739.00 05/27/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431128
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 04/30/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192159903
Principal investigator 1 GlaxoSmithKline, LLC. $12,500.00 04/30/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192159907
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 04/30/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192159912
Principal investigator 1 GlaxoSmithKline, LLC. $2,850.00 04/30/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192159917
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,739.00 04/17/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431126
Principal investigator 1 GlaxoSmithKline, LLC. $19,852.25 04/08/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192160547
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,478.00 03/24/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431124
Principal investigator 1 GlaxoSmithKline, LLC. $19,719.73 03/21/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192159925
Principal investigator 1 GlaxoSmithKline, LLC. $19,624.10 02/24/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192159921
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,884.00 02/19/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431118
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,284.00 02/19/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431120
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $512.00 02/19/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431122
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,891.00 02/07/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431116
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $55.00 01/17/2025 Non-covered Recipient Entity
Clinical Trial Source
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431114
Principal investigator 1 GlaxoSmithKline, LLC. $12,926.98 01/08/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192160516
Principal investigator 1 GlaxoSmithKline, LLC. $8,948.61 01/08/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192160538